Tags

Type your tag names separated by a space and hit enter

B-cell depletion therapy for multiple sclerosis.
Immunol Med. 2021 Jul 21 [Online ahead of print]IM

Abstract

Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients in the 1940s, B cells have been considered to participate in the pathology of MS through the production of autoantibodies reactive against central nervous system antigens. However, it is now recognized that B cells contribute to MS relapses via antibody-independent activities, including the presentation of antigens to T cells and the release of pro-inflammatory cytokines. In addition, the recent identification of B cell-rich follicle-like structures in the meninges of progressive MS patients suggests that the pathogenic roles of B cells also exist at the progressive phase of this disease. Recently, large-scale clinical trials have demonstrated the efficacy of B-cell depletion therapy using anti-CD20 antibodies in relapsing as well as primary progressive MS. B-cell depletion therapy has become an essential treatment option for MS based on its unique benefit to risk balance in relapsing MS, and because it is the only drug that has been shown to be effective in primary progressive MS to date.

Authors+Show Affiliations

Department of Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34289331

Citation

Miyazaki, Yusei, and Masaaki Niino. "B-cell Depletion Therapy for Multiple Sclerosis." Immunological Medicine, 2021, pp. 1-9.
Miyazaki Y, Niino M. B-cell depletion therapy for multiple sclerosis. Immunol Med. 2021.
Miyazaki, Y., & Niino, M. (2021). B-cell depletion therapy for multiple sclerosis. Immunological Medicine, 1-9. https://doi.org/10.1080/25785826.2021.1952543
Miyazaki Y, Niino M. B-cell Depletion Therapy for Multiple Sclerosis. Immunol Med. 2021 Jul 21;1-9. PubMed PMID: 34289331.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - B-cell depletion therapy for multiple sclerosis. AU - Miyazaki,Yusei, AU - Niino,Masaaki, Y1 - 2021/07/21/ PY - 2021/7/21/entrez PY - 2021/7/22/pubmed PY - 2021/7/22/medline KW - Anti-CD20 antibody KW - B cells KW - coronavirus disease KW - multiple sclerosis KW - progressive multifocal leukoencephalopathy SP - 1 EP - 9 JF - Immunological medicine JO - Immunol Med N2 - Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients in the 1940s, B cells have been considered to participate in the pathology of MS through the production of autoantibodies reactive against central nervous system antigens. However, it is now recognized that B cells contribute to MS relapses via antibody-independent activities, including the presentation of antigens to T cells and the release of pro-inflammatory cytokines. In addition, the recent identification of B cell-rich follicle-like structures in the meninges of progressive MS patients suggests that the pathogenic roles of B cells also exist at the progressive phase of this disease. Recently, large-scale clinical trials have demonstrated the efficacy of B-cell depletion therapy using anti-CD20 antibodies in relapsing as well as primary progressive MS. B-cell depletion therapy has become an essential treatment option for MS based on its unique benefit to risk balance in relapsing MS, and because it is the only drug that has been shown to be effective in primary progressive MS to date. SN - 2578-5826 UR - https://www.unboundmedicine.com/medline/citation/34289331/B-cell_depletion_therapy_for_multiple_sclerosis. L2 - https://www.tandfonline.com/doi/full/10.1080/25785826.2021.1952543 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.